| pubmed-article:17016026 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17016026 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:17016026 | lifeskim:mentions | umls-concept:C0302353 | lld:lifeskim |
| pubmed-article:17016026 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17016026 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:17016026 | lifeskim:mentions | umls-concept:C0074444 | lld:lifeskim |
| pubmed-article:17016026 | lifeskim:mentions | umls-concept:C1138004 | lld:lifeskim |
| pubmed-article:17016026 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:17016026 | pubmed:dateCreated | 2006-10-3 | lld:pubmed |
| pubmed-article:17016026 | pubmed:abstractText | Typical adverse effects of Shakuyaku-kanzo-To (SKT), an herbal medicine containing licorice, is a licorice-induced pseudoaldosteronism with hypokalemia and hypertension. The risk factors for this side effect are still unclear. To identify the risk factors, we surveyed 37 cases of licorice-induced pseudoaldosteronism in the literature and serum potassium levels in our patients receiving SKT and Shosaiko-To (SST), which contain 6 g and 1.5 g of licorice in the daily dose, respectively. In the case report survey, pseudoaldosteronism developed a median 35 (range 2-231) days after the administration of SKT, which is shorter than after SST (450, range 150-2190 days) and other licorice products including glycyrrhizin (210, range 14-730 days). A significant correlation was observed between the glycyrrhizin contents in the licorice preparations and the dosing periods for developing pseudoaldosteronism (r=-0.700, p<0.01). A negative correlation was also observed between serum potassium level and dosing period for SKT, but not for SST. The difference in age (65.3+/-11.6 vs. 57.2+/-17.3 y) and dosing period (57.3+/-66.3 vs. 19.0+/-24.3 days) between the patients with and without hypokalemia after the administration of SKT was statistically significant (p<0.05). The occurrence rate of hypokalemia including pseudoaldosteronism was around 80% with SKT administration for more than 30 days for patients exceeding 60 years old. It was suggested that patient age (>60 y) and dosing period of SKT (>30 days) might be risk factors for developing pseudoaldosteronism or hypokalemia as well as coadministration of drugs inducing hypokalemia. | lld:pubmed |
| pubmed-article:17016026 | pubmed:language | jpn | lld:pubmed |
| pubmed-article:17016026 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17016026 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17016026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17016026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17016026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17016026 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17016026 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17016026 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:17016026 | pubmed:issn | 0031-6903 | lld:pubmed |
| pubmed-article:17016026 | pubmed:author | pubmed-author:HommaMasatoM | lld:pubmed |
| pubmed-article:17016026 | pubmed:author | pubmed-author:KohdaYukinaoY | lld:pubmed |
| pubmed-article:17016026 | pubmed:author | pubmed-author:IshiharaMiyaM | lld:pubmed |
| pubmed-article:17016026 | pubmed:author | pubmed-author:QianWenW | lld:pubmed |
| pubmed-article:17016026 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17016026 | pubmed:volume | 126 | lld:pubmed |
| pubmed-article:17016026 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17016026 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17016026 | pubmed:pagination | 973-8 | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:meshHeading | pubmed-meshheading:17016026... | lld:pubmed |
| pubmed-article:17016026 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17016026 | pubmed:articleTitle | [Effects of long term administration of Shakuyaku-kanzo-To and Shosaiko-To on serum potassium levels]. | lld:pubmed |
| pubmed-article:17016026 | pubmed:affiliation | Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, and Department of Pharmacy, Tsukuba University Hospital, Ibaraki, Japan. masatoh@md.tsukuba.ac.jp | lld:pubmed |
| pubmed-article:17016026 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17016026 | pubmed:publicationType | English Abstract | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17016026 | lld:pubmed |
